ZURA BIO LIMITED Temporary Equity, Accretion to Redemption Value, Adjustment
ZURA BIO LIMITED (ZURA) reported Temporary Equity, Accretion to Redemption Value, Adjustment of -$4.87 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment · last filed 2026-03-19
- ZURA BIO LIMITED temporary equity, accretion to redemption value, adjustment for the quarter ending 2025-12-31 was -$7.70M.
- ZURA BIO LIMITED temporary equity, accretion to redemption value, adjustment for the quarter ending 2025-09-30 was $2.83M, a 26.25% increase year-over-year.
- ZURA BIO LIMITED temporary equity, accretion to redemption value, adjustment for the quarter ending 2024-09-30 was $2.24M.
- ZURA BIO LIMITED temporary equity, accretion to redemption value, adjustment for the quarter ending 2024-06-30 was $2.34M.
- ZURA BIO LIMITED temporary equity, accretion to redemption value, adjustment for fiscal 2025 was -$4.87M.
- ZURA BIO LIMITED temporary equity, accretion to redemption value, adjustment for fiscal 2023 was $7.22M.
- ZURA BIO LIMITED temporary equity, accretion to redemption value, adjustment for fiscal 2021 was $19.16M.
| Period end | Temporary Equity, Accretion to Redemption Value, Adjustment 3 month | Temporary Equity, Accretion to Redemption Value, Adjustment 6 month | Temporary Equity, Accretion to Redemption Value, Adjustment 7 month | Temporary Equity, Accretion to Redemption Value, Adjustment 7 month as first filed | Temporary Equity, Accretion to Redemption Value, Adjustment 9 month | Temporary Equity, Accretion to Redemption Value, Adjustment 10 month | Temporary Equity, Accretion to Redemption Value, Adjustment 11 month | Temporary Equity, Accretion to Redemption Value, Adjustment 12 month | Temporary Equity, Accretion to Redemption Value, Adjustment 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$4.87M derived: sum of 2 quarters · filed 2026-03-19 | -$4.87M 10-K · filed 2026-03-19 | ||||||
| 2025-09-30 | $2.83M 10-Q · filed 2025-11-13 | $2.83M 10-Q · filed 2025-11-13 | |||||||
| 2024-09-30 | $2.24M 10-Q · filed 2025-11-13 | $4.58M derived: sum of 2 quarters · filed 2025-11-13 | $4.58M 10-Q · filed 2025-11-13 | ||||||
| 2024-06-30 | $2.34M 10-Q · filed 2025-08-14 | $2.34M 10-Q · filed 2025-08-14 | |||||||
| 2023-12-31 | $7.02M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $7.02M derived: sum of 2 quarters · filed 2025-03-25 | $7.02M derived: sum of 3 quarters · filed 2025-03-25 | $7.22M 10-K · filed 2025-03-25 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $0.00 derived: sum of 2 quarters · filed 2024-11-07 | $203.00K 10-Q · filed 2024-11-07 | ||||||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $203.00K 10-Q · filed 2024-08-13 | |||||||
| 2023-03-31 | $203.00K 10-Q · filed 2024-05-09 | ||||||||
| 2022-12-31 | $6.65M 10-K · filed 2024-03-28 | ||||||||
| 2021-12-31 | $20.79M 10-K · filed 2023-03-28 | $19.16M 10-K · filed 2023-03-28 | $20.79M 10-Q · filed 2022-08-12 | ||||||
| 2021-09-30 | $20.79M 10-Q · filed 2022-11-14 | $20.79M 10-Q/A · filed 2022-04-25 | $16.35M 10-Q · filed 2021-11-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |